A Phase 3, Long-Term, Open-Label Safety Study of Self-Administered Galcanezumab Injections in Patients with Migraine

被引：0
|
作者：
Stauffer, Virginia L. [1 ]
Sides, Ryan [1 ]
Camporeale, Angelo [1 ]
Skljarevski, Vladimir [1 ]
Ahl, Jonna [1 ]
Aurora, Sheena K. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
来源：
CEPHALALGIA | 2017年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PO-01-184
引用
收藏
页码：330 / 331
页数：2
相关论文
共 50 条
  • [31] Safety of long-term use of linezolid: results of an open-label study
    Vazquez, Jose A.
    Arnold, Anthony C.
    Swanson, Robert N.
    Biswas, Pinaki
    Bassetti, Matteo
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2016, 12 : 1347 - 1354
  • [32] Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema
    Aberer, W.
    Maurer, M.
    Reshef, A.
    Longhurst, H.
    Kivity, S.
    Bygum, A.
    Caballero, T.
    Bloom, B.
    Nair, N.
    Malbran, A.
    ALLERGY, 2014, 69 (03) : 305 - 314
  • [33] An open-label study to evaluate the long-term safety of zelrix™, a sumatriptan iontophoretic patch for the treatment of acute migraine
    Smith, T.
    Pierce, M.
    Griesser, J.
    Sebree, T.
    O'Neill, C.
    CEPHALALGIA, 2011, 31 (01) : 120 - 120
  • [34] Long-Term, Open-Label Safety Study of Oral Almotriptan 12.5 mg for the Acute Treatment of Migraine in Adolescents
    Berenson, Frank
    Vasconcellos, Elza
    Pakalnis, Ann
    Mao, Lian
    Biondi, David M.
    Armstrong, Robert B.
    HEADACHE, 2010, 50 (05): : 795 - 807
  • [35] Safety of Rimegepant in Adults with Migraine and Cardiovascular Risk Factors: Analysis of a Multicenter, Long-Term, Open-Label Study
    True, David
    Mullin, Kathleen
    Croop, Robert
    PAIN AND THERAPY, 2024, 13 (05) : 1203 - 1218
  • [36] Long-Term Cardiovascular Safety of Lasmiditan for the Acute Treatment of Migraine for up to One Year: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)
    Rosen, N. L.
    Mathew, P. G.
    Buchanan, A. S.
    Baygani, S.
    Hochstetler, H.
    Khanna, R.
    HEADACHE, 2020, 60 : 111 - 111
  • [37] Shift from Chronic Migraine to Episodic Migraine Status in a Long-Term Phase 3 Study of Galcanezumab
    Hindiyeh, N. A.
    Detke, H. C.
    Day, K.
    Lipsius, S.
    Aurora, S. K.
    Diener, H.
    HEADACHE, 2019, 59 : 103 - 103
  • [38] A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
    Croop, Robert
    Madonia, Jennifer
    Hould, Jennifer
    Mosher, Linda
    Lovegren, Meghan
    Lipton, Richard
    NEUROLOGY, 2023, 100 (17)
  • [39] LONG-TERM CARDIOVASCULAR SAFETY OF LASMIDITAN FOR THE ACUTE TREATMENT OF MIGRAINE FOR UP TO ONE YEAR: INTERIM RESULTS OF AN OPEN-LABEL PHASE 3 STUDY (GLADIATOR)
    Buchanan, Andrew
    Baygani, Simin K.
    Rosen, Noah
    Mathew, Paul G.
    Hochstetler, Helen
    Khanna, Rashna
    CEPHALALGIA, 2020, 40 : 49 - 50
  • [40] A Phase 2/3 Open-label, Long-term, Safety Trial of Zavegepant 10 mg Nasal Spray for the Acute Treatment of Migraine
    Croop, R.
    Madonia, J.
    Hould, J.
    Mosher, L.
    Lovegren, M.
    Coric, V.
    Lipton, R.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
12345